Free Trial

Celularity (CELU) 10K Form and Latest SEC Filings 2026

Celularity logo
$1.02 -0.04 (-3.77%)
Closing price 04:00 PM Eastern
Extended Trading
$1.02 0.00 (-0.39%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Celularity SEC Filings & Recent Activity

Celularity (NASDAQ:CELU) has submitted 386+ documents to the U.S. Securities and Exchange Commission (SEC) since 2019. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on June 3, 2026.

Form 4
Celularity Inc Reports Ownership Change on Apr. 15, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Celularity Files Current Report on Jun. 3, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Celularity Files Annual Report on Apr. 30, 2026

The 10-K contains Celularity's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Celularity SEC Filing History

Browse Celularity's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/28/2026 3:54 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/30/2026 3:06 PM
Celularity (1752828) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
04/24/2026 5:40 PM
Celularity (1752828) Issuer
Philip & Daniele Barach Family Trust (2107059) Reporting
Form 3
Initial statement of beneficial ownership of securities  
04/24/2026 5:41 PM
Barach Daniele Wolf (2126385) Reporting
Celularity (1752828) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/24/2026 5:41 PM
Barach Philip Alan (2106805) Reporting
Celularity (1752828) Issuer
Form 3
Initial statement of beneficial ownership of securities  
04/22/2026 9:16 AM
Celularity (1752828) Subject
Philip & Daniele Barach Family Trust (2107059) Filed by
Form SCHEDULE 13D/A
04/21/2026 8:05 AM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/15/2026 3:30 PM
Celularity (1752828) Issuer
Hariri Robert J (1398815) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:30 PM
Celularity (1752828) Issuer
Haines John R (1867686) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/15/2026 3:30 PM
Brigido Stephen (1869791) Reporting
Celularity (1752828) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
04/03/2026 10:08 AM
Celularity (1752828) Subject
Philip & Daniele Barach Family Trust (2107059) Filed by
Form SCHEDULE 13D
03/31/2026 4:13 PM
Celularity (1752828) Filer
Form NT 10-K
03/10/2026 8:00 AM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/21/2026 3:30 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/15/2026 3:15 PM
Celularity (1752828) Issuer
Ling Geoffrey M.D. (1800097) Reporting
Form 4/A
01/15/2026 3:15 PM
Celularity (1752828) Issuer
LeVien Vincent (2076464) Reporting
Form 4/A
01/15/2026 3:15 PM
Celularity (1752828) Issuer
Diamandis Peter (1528288) Reporting
Form 4/A
01/15/2026 3:15 PM
Celularity (1752828) Issuer
Parks Diane L. (1781026) Reporting
Form 4/A
01/14/2026 7:55 PM
Celularity (1752828) Issuer
Ling Geoffrey M.D. (1800097) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:51 PM
Celularity (1752828) Issuer
Parks Diane L. (1781026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:51 PM
Celularity (1752828) Issuer
Diamandis Peter (1528288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2026 7:53 PM
Celularity (1752828) Issuer
LeVien Vincent (2076464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
01/07/2026 11:15 PM
Celularity (1752828) Filer
Form EFFECT
01/08/2026 5:15 AM
Celularity (1752828) Filer
Form 424B3
12/31/2025 3:15 PM
Celularity (1752828) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/30/2025 3:30 PM
Celularity (1752828) Issuer
Diamandis Peter (1528288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:30 PM
Celularity (1752828) Issuer
Parks Diane L. (1781026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:30 PM
Celularity (1752828) Issuer
Ling Geoffrey M.D. (1800097) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/30/2025 3:30 PM
Celularity (1752828) Issuer
LeVien Vincent (2076464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/29/2025 11:15 PM
Celularity (1752828) Filer
Form EFFECT
12/30/2025 5:04 AM
Celularity (1752828) Filer
Form 424B3
12/23/2025 3:15 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/22/2025 3:30 PM
Celularity (1752828) Issuer
Diamandis Peter (1528288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:30 PM
Celularity (1752828) Issuer
Ling Geoffrey M.D. (1800097) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/22/2025 3:30 PM
Celularity (1752828) Issuer
Parks Diane L. (1781026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
12/19/2025 3:15 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/19/2025 3:15 PM
Celularity (1752828) Filer
Form S-1
Registration statement under Securities Act of 1933  
12/05/2025 3:30 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/21/2025 3:15 PM
Celularity (1752828) Issuer
Diamandis Peter (1528288) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 3:15 PM
Celularity (1752828) Issuer
Ling Geoffrey M.D. (1800097) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/21/2025 3:17 PM
Celularity (1752828) Issuer
LeVien Vincent (2076464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (Ad)

Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel

Get the name and ticker of Louis Navellier's #1 AI stock free
11/21/2025 3:17 PM
Celularity (1752828) Issuer
Parks Diane L. (1781026) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/07/2025 4:08 PM
Celularity (1752828) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
11/07/2025 12:13 PM
Celularity (1752828) Filer
Form DEF 14A
11/07/2025 12:19 PM
Celularity (1752828) Filer
Form ARS
11/07/2025 12:21 PM
Celularity (1752828) Filer
Form DEFA14A
11/03/2025 4:07 PM
Celularity (1752828) Filer
Form D
Notice of Exempt Offering of Securities 
10/28/2025 8:29 AM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/29/2025 4:17 PM
Celularity (1752828) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/29/2025 4:21 PM
Celularity (1752828) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
08/27/2025 8:15 AM
Celularity (1752828) Subject
Lincoln Alternative Strategies LLC (2043812) Filed by
Form SCHEDULE 13G
08/18/2025 3:30 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/05/2025 5:15 AM
Celularity (1752828) Filer
Form D
Notice of Exempt Offering of Securities 
08/05/2025 5:15 AM
Celularity (1752828) Filer
Form D
Notice of Exempt Offering of Securities 
08/05/2025 5:16 AM
Celularity (1752828) Filer
Form D
Notice of Exempt Offering of Securities 
08/01/2025 5:30 AM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/30/2025 3:30 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/29/2025 3:18 PM
Celularity (1752828) Filer
Form 8-K/A
07/28/2025 8:40 PM
Celularity (1752828) Issuer
Genting Berhad (1788489) Reporting
Lim Kok Thay (1470308) Reporting
Resorts World Inc Pte. Ltd. (2007400) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/28/2025 8:44 PM
Celularity (1752828) Subject
Dragasac Ltd (1872884) Filed by
Form SCHEDULE 13D/A
07/28/2025 3:30 PM
Celularity (1752828) Issuer
LeVien Vincent (2076464) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2025 7:24 AM
Celularity (1752828) Issuer
DosSantos Joseph (1607233) Reporting
Form 3
Initial statement of beneficial ownership of securities  
07/10/2025 8:28 AM
Celularity (1752828) Issuer
LeVien Vincent (2076464) Reporting
Form 3
Initial statement of beneficial ownership of securities  
06/06/2025 3:30 PM
Celularity (1752828) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/04/2025 3:30 PM
Celularity (1752828) Issuer
Hariri Robert J (1398815) Reporting
Form 4/A
(Data available from 1/1/2016 forward)

Celularity SEC Filings - Frequently Asked Questions

Celularity (CELU) has submitted 386+ filings to the SEC since 2019. You can browse the complete history or filter by form type using the tools above.

Celularity's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results.

The most recent filing was a Form 8-K submitted on June 3, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NASDAQ:CELU) was last updated on 6/3/2026 by MarketBeat.com Staff.
From Our Partners